incretin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-25. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
== K == K-selection – Kary Mullis – karyoplasm – karyotype – keratin – keystone species – kidney – kinesiology – kinetic energy – Klinefelter syndrome – knock-out mouse – Konrad Lorenz – Krebs cycle (or citric acid cycle) – KSL cells - kwashiorkor
=== Pharmacodynamics === Nor-LSD showed 5- to 29-fold lower affinity for the serotonin 5-HT2 receptor compared to LSD (Ki = 30–158 nM vs. 5.4 nM, respectively). It also showed affinity for the serotonin 5-HT1 receptor. In another more recent study however, nor-LSD showed similar or even higher affinities, activational potencies, and/or efficacies at the serotonin 5-HT1A, 5-HT2A, and 5-HT2B receptors as LSD, whereas it showed 36-fold lower affinity for the serotonin 5-HT2C receptor compared to LSD. Nor-LSD failed to completely substitute for LSD in rodent drug discrimination tests even at very high doses. The greatest degree of substitution with nor-LSD was 75% at a dose of 7,420 nM/kg, whereas 100% substitution occurred with LSD at a dose of 186 nM/kg (a 40-fold lower dose). The ED50Tooltip median effective dose was 2,594 nM/kg for nor-LSD and 46 nM/kg for LSD. Hence, nor-LSD was approximately 56-fold less potent than LSD in terms of producing LSD-like effects in rodents and failed to produce full LSD-like effects even at the highest assessed dose. In another study, nor-LSD failed to produce LSD-like electroencephalogram (EEG) changes in rabbits.
anti-emetics IV antibiotics intravenous fluids with electrolytes injections of vitamin B plasma or whole blood transfusion Feeding should be continued as long as possible. A highly digestible diet is preferred, but the individual animal's preferences may dictate giving whatever it will eat. In anorexic, hypoproteinemic, vomiting and diarrheic cats parenteral nutrition is required. In a disease outbreak, unvaccinated kittens or adults can be given anti-FPV serum containing FPV antibodies injected subcutaneously or intraperitoneal. This may provide protection for 2–4 weeks. Therapeutic efficacy of anti-FPV serum has been demonstrated in dogs, and similar beneficial effects may be expected in cats. Several studies have shown recombinant feline interferon omega is effective in the treatment of parvoviral enteritis in dogs and also inhibits replication of FPV in cell culture. So far no data are available on its efficacy in FPV-infected cats.
Sources: en.wikipedia.org
Radium was once an additive in products such as cosmetics, soap, razor blades, and even beverages due to its supposed curative powers. Many contemporary products were falsely advertised as being radioactive. Such products soon fell out of vogue and were prohibited by authorities in many countries after it was discovered they could have serious adverse health effects. (See, for instance, Radithor or Revigator types of "radium water" or "Standard Radium Solution for Drinking".) Spas featuring radium-rich water are still occasionally touted as beneficial, such as those in Misasa, Tottori, Japan, though the sources of radioactivity in these spas vary and may be attributed to radon and other radioisotopes.
Relugolix, sold under the brand names Orgovyx and Relumina among others, is a gonadotropin-releasing hormone antagonist (GnRH receptor antagonist) medication which is used in the treatment of prostate cancer, uterine fibroids and endometriosis. It is taken by mouth. Side effects of relugolix include menstrual abnormalities, hot flashes, excessive sweating, headache, and decreased bone mineral density. Relugolix is a GnRH antagonist, or an antagonist of the gonadotropin-releasing hormone receptor. Unlike most other GnRH modulators, but similarly to elagolix (brand name Orilissa), relugolix is a non-peptide, small-molecule compound and is orally active. It suppresses sex hormone levels to the postmenopausal or castrate range in both women and men.
Aquileia is a smaller town today than the colony first founded by Rome. Over the centuries, sieges, earthquakes, floods and pillaging of the ancient buildings for materials mean that no building from the Roman period remain above ground. The site of Aquileia is believed to be the largest Roman city yet to be excavated and is on the UNESCO World Heritage List. Excavations, however, have revealed some of the layout of the Roman town like a segment of a street, the north-western angle of the town walls; the river port; and the former locations of baths, an amphitheatre, a circus, a cemetery, the Via Sacra, the forum and a market. The National Archaeological Museum of Aquileia contains over 2,000 inscriptions, statues and other antiquities and mosaics, as well as glasses of local production and a collection.
Sources: en.wikipedia.org
Before amylin deposition was associated with diabetes, already in 1901, scientists described the phenomenon of "islet hyalinization", which could be found in some cases of diabetes. A thorough study of this phenomenon was possible much later. In 1986, the isolation of an aggregate from an insulin-producing tumor was successful, a protein called IAP (Insulinoma Amyloid Peptide) was characterized, and amyloids were isolated from the pancreas of a diabetic patient, but the isolated material was not sufficient for full characterization. This was achieved only a year later by two research teams whose research was a continuation of the work from 1986.
229Th has a nuclear isomer, 229mTh, with an excitation energy of 8.355733554021(8) eV. This is by far the lowest of all nuclear isomers. Because this energy lies between thorium's first and second ionization energies of 6.3 and 11.5 eV, the decay rate of 229mTh is sensitive to the electronic environment of the nucleus. In neutral 229mTh, the isomer decays by internal conversion to 229Th+ within a few microseconds. However, the isomeric energy is not enough to remove a second electron, so internal conversion is impossible in 229mTh+ ions; they are forced to decay radiatively with a half-life 8.4 orders of magnitude longer, in excess of 1000 seconds. Embedded in ionic crystals, ionization is not quite 100%, so a small amount of internal conversion occurs, leading to a recently measured lifetime of ≈600 s, which can be extrapolated to a lifetime for isolated ions of 1740±50 s. Any photon emitted by nuclear decay is called a gamma ray, but this "gamma ray" has a frequency of 2020407384335±2 kHz (wavelength 148.3821828827(15) nm), in te far ultraviolet. This means it is possible to build a laser operating at this frequency, giving the only known opportunity for direct laser excitation of a nuclear state. This could have applications like a nuclear clock of very high accuracy or as a qubit for quantum computing. These applications were for a long time impeded by imprecise measurements of the isomeric energy, as laser excitation's exquisite precision makes it difficult to use to search a wide frequency range.
This is a list of prices of chemical elements. Listed here are mainly average market prices for bulk trade of commodities. Data on elements' abundance in Earth's crust is added for comparison. As of 2025, the most expensive non-synthetic element by mass is rhodium, and by volume, iridium. It is followed by rhodium, caesium, iridium and palladium by mass and iridium, gold and platinum by volume. Carbon in the form of diamond can be more expensive than rhodium. Per-kilogram prices of some synthetic radioisotopes range to trillions of dollars. While the difficulty of obtaining macroscopic samples of synthetic elements in part explains their high value, there has been interest in converting base metals to gold (chrysopoeia) since ancient times, but only deeper understanding of nuclear physics has allowed the actual production of a tiny amount of gold from other elements for research purposes as demonstrated by Glenn Seaborg. However, both this and other routes of synthesis of precious metals via nuclear reactions is orders of magnitude removed from economic viability. Chlorine, sulfur and carbon (as coal) are cheapest by mass. Hydrogen, nitrogen, oxygen and chlorine are cheapest by volume at atmospheric pressure. When there is no public data on the element in its pure form, price of a compound is used, per mass of element contained. This implicitly puts the value of compounds' other constituents, and the cost of extraction of the element, at zero. For elements whose radiological properties are important, individual isotopes and isomers are listed.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.